Categories: Health

US giant Merck allows generic manufacture of its new medicine for Covid, 5 Indian firms in list

<p>
American pharmaceuticals giant Merck & Co has signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) that will allow more companies to manufacture generic versions of its oral antiviral COVID-19 medicine, the company announced on Wednesday.</p>
<p>
Merck said the royalty-free license would apply to 105 low- and middle-income countries. It allows manufacturers selected by MPP to make generic versions of molnupiravir, the antiviral pill Merck has developed with Ridgeback Biotherapeutics.</p>
<p>
The U.S. Food and Drug Administration is considering emergency use authorization of the medicine, which proved in a clinical trial that it could reduce by 50% the risk of serious disease and death when given early COVID-19 patients.</p>
<p>
"This is the first transparent, public health-driven voluntary license for a COVID-19 medical technology," Merck and MPP said in a joint statement.</p>
<p>
<strong>Also read: </strong> <a href="https://www.indianarrative.com/science-news/pharma-giant-merck-s-new-pill-can-be-game-changer-in-war-on-covid-indian-firms-to-produce-drug-too-118738.html">Pharma giant Merck’s new pill can be game-changer in war on Covid, 5 Indian firms to produce drug too</a></p>
<p>
Companies will be able to apply for a sub-license from MPP and the license, which also includes technology transfer, will remain royalty-free so long as the World Health Organization classifies the pandemic as a "Public Health Emergency of International Concern," the statement said.</p>
<p>
Merck & Co had announced in April that it has signed an agreement to partner five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd , to expand production and marketing of its experimental COVID-19 drug. The three other companies are Dr.Reddy's Laboratories Ltd  and privately held companies Emcure Pharmaceuticals Ltd and Hetero Labs Ltd.</p>
<p>
The partnership will give the companies license to supply Merck's molnupiravir to India and more than 100 low and middle-income countries following approvals or emergency authorization by local regulatory agencies, Merck said.</p>

IN Bureau

Recent Posts

India charts bold path to global 6G leadership, Minister Scindia reviews progress in Bengaluru

Union Minister for Communications Jyotiraditya Scindia chaired a key meeting with the Bharat 6G Alliance…

12 hours ago

Japanese envoy urges Taliban to reopen schools for girls, warns of healthcare crisis

Japanese Ambassador in Kabul, Takayoshi Kuromaya, has called on the Taliban government in Afghanistan to…

13 hours ago

Digital India Foundation opposes Pakistan’s membership bid to AI Alliance Network; cites security concerns

The Digital India Foundation (DIF), a founding member of the AI Alliance Network (AIANET), has…

13 hours ago

Gold’s rally awaits clarity on US interest rates and dollar weakness: Report

Current bullion market is focusing on a combination of factors which includes direction of US…

17 hours ago

“You show me one photograph…” NSA Ajit Doval slams foreign media’s coverage of Operation Sindoor

National Security Advisor Ajit Doval on Friday slammed foreign media for their reportage of Operation…

17 hours ago

Russia: Bharat Utsav celebrates India’s rich heritage, culture and traditions

The Bharat Utsav, a festival celebrating India's rich culture, heritage, and tradition, has begun in…

19 hours ago